{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T15:39:09Z","timestamp":1774280349193,"version":"3.50.1"},"reference-count":119,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T00:00:00Z","timestamp":1682294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R00HL151965"],"award-info":[{"award-number":["R00HL151965"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["OLIVER22A0-KB"],"award-info":[{"award-number":["OLIVER22A0-KB"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Genet."],"abstract":"<jats:p>Cystic fibrosis (CF) is an autosomal recessive disease impacting \u223c100,000 people worldwide. This lethal disorder is caused by mutation of the <jats:italic>CF<\/jats:italic><jats:italic>transmembrane conductance regulator (CFTR)<\/jats:italic> gene, which encodes an ATP-binding cassette-class C protein. More than 2,100 variants have been identified throughout the length of <jats:italic>CFTR<\/jats:italic>. These defects confer differing levels of severity in mRNA and\/or protein synthesis, folding, gating, and turnover. Drug discovery efforts have resulted in recent development of modulator therapies that improve clinical outcomes for people living with CF. However, a significant portion of the CF population has demonstrated either no response and\/or adverse reactions to small molecules. Additional therapeutic options are needed to restore underlying genetic defects for all patients, particularly individuals carrying rare or refractory <jats:italic>CFTR<\/jats:italic> variants. Concerted focus has been placed on rescuing variants that encode truncated CFTR protein, which also harbor abnormalities in mRNA synthesis and stability. The current mini-review provides an overview of CFTR mRNA features known to elicit functional consequences on final protein conformation and function, including considerations for RNA-directed therapies under investigation. Alternative exon usage in the 5\u2032-untranslated region, polypyrimidine tracts, and other sequence elements that influence splicing are discussed. Additionally, we describe mechanisms of CFTR mRNA decay and post-transcriptional regulation mediated through interactions with the 3\u2032-untranslated region (e.g. poly-uracil sequences, microRNAs). Contributions of synonymous single nucleotide polymorphisms to CFTR transcript utilization are also examined. Comprehensive understanding of CFTR RNA biology will be imperative for optimizing future therapeutic endeavors intended to address presently untreatable forms of CF.<\/jats:p>","DOI":"10.3389\/fgene.2023.1166529","type":"journal-article","created":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T11:42:34Z","timestamp":1682336554000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Features of CFTR mRNA and implications for therapeutics development"],"prefix":"10.3389","volume":"14","author":[{"given":"JaNise J.","family":"Jackson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiyang","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"Tyshawn R.","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Foye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn E.","family":"Oliver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s11883-021-00914-7","article-title":"ANGPTL3 and apolipoprotein C-III as novel lipid-lowering targets","volume":"23","author":"Akoumianakis","year":"2021","journal-title":"Curr. Atheroscler. Rep."},{"key":"B2","doi-asserted-by":"publisher","first-page":"3850","DOI":"10.1038\/s41467-021-24076-x","article-title":"Repurposing tRNAs for nonsense suppression","volume":"12","author":"Albers","year":"2021","journal-title":"Nat. Commun."},{"key":"B3","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1096\/fj.15-273714","article-title":"A synonymous codon change alters the drug sensitivity of \u0394F508 cystic fibrosis transmembrane conductance regulator","volume":"30","author":"Bali","year":"2016","journal-title":"Faseb J."},{"key":"B4","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/life11010014","article-title":"The effect of synonymous single-nucleotide polymorphisms on an atypical cystic fibrosis clinical presentation","volume":"11","author":"Bampi","year":"2020","journal-title":"Life (Basel)"},{"key":"B5","doi-asserted-by":"publisher","first-page":"3692","DOI":"10.1093\/nar\/gkab194","article-title":"Effect of small molecule eRF3 degraders on premature termination codon readthrough","volume":"49","author":"Baradaran-Heravi","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e1003529","DOI":"10.1371\/journal.pgen.1003529","article-title":"Gene expression regulation by upstream open reading frames and human disease","volume":"9","author":"Barbosa","year":"2013","journal-title":"PLoS Genet."},{"key":"B7","doi-asserted-by":"publisher","first-page":"28741","DOI":"10.1074\/jbc.M110.154575","article-title":"A synonymous single nucleotide polymorphism in DeltaF508 CFTR alters the secondary structure of the mRNA and the expression of the mutant protein","volume":"285","author":"Bartoszewski","year":"2010","journal-title":"J. Biol. Chem."},{"key":"B8","doi-asserted-by":"publisher","first-page":"C1240","DOI":"10.1152\/ajpcell.00595.2004","article-title":"Cell-specific posttranscriptional regulation of CFTR gene expression via influence of MAPK cascades on 3'UTR part of transcripts","volume":"289","author":"Baudouin-Legros","year":"2005","journal-title":"Am. J. Physiol. Cell. Physiol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/nsmb.2057","article-title":"Structure of the no-go mRNA decay complex Dom34-Hbs1 bound to a stalled 80S ribosome","volume":"18","author":"Becker","year":"2011","journal-title":"Nat. Struct. Mol. Biol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1074\/jbc.R700033200","article-title":"Genome-wide analysis of alternative pre-mRNA splicing","volume":"283","author":"Ben-Dov","year":"2008","journal-title":"J. Biol. Chem."},{"key":"B11","doi-asserted-by":"publisher","first-page":"810956","DOI":"10.3390\/ijms231810956","article-title":"The CFTR Amplifier Nesolicaftor Rescues TGF-\u03b21 Inhibition of Modulator-Corrected F508del CFTR Function","volume":"23","author":"Bengtson","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1093\/emboj\/20.7.1774","article-title":"Nuclear factor TDP-43 and SR proteins promote in vitro and in vivo CFTR exon 9 skipping","volume":"20","author":"Buratti","year":"2001","journal-title":"Embo J."},{"key":"B13","doi-asserted-by":"publisher","first-page":"4369","DOI":"10.1093\/nar\/gkm447","article-title":"RNA structure is a key regulatory element in pathological ATM and CFTR pseudoexon inclusion events","volume":"35","author":"Buratti","year":"2007","journal-title":"Nucleic Acids Res."},{"key":"B14","volume-title":"ReCode Therapeutics announces strategic investment from the Cystic Fibrosis Foundation to accelerate development of novel mRNA therapy [press release]","year":"2023"},{"key":"B15","doi-asserted-by":"publisher","first-page":"7507","DOI":"10.1073\/pnas.0810916106","article-title":"Upstream open reading frames cause widespread reduction of protein expression and are polymorphic among humans","volume":"106","author":"Calvo","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B16","first-page":"623","article-title":"A novel donor splice site in intron 11 of the CFTR gene, created by mutation 1811+1.6kbA-->G, produces a new exon: High frequency in Spanish cystic fibrosis chromosomes and association with severe phenotype","volume":"56","author":"Chill\u00f3n","year":"1995","journal-title":"Am. J. Hum. Genet."},{"key":"B17","doi-asserted-by":"publisher","first-page":"24471","DOI":"10.1016\/s0021-9258(18)54252-6","article-title":"Characterization of the promoter region of the cystic fibrosis transmembrane conductance regulator gene","volume":"266","author":"Chou","year":"1991","journal-title":"J. Biol. Chem."},{"key":"B18","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/ng0293-151","article-title":"Genetic basis of variable exon 9 skipping in cystic fibrosis transmembrane conductance regulator mRNA","volume":"3","author":"Chu","year":"1993","journal-title":"Nat. Genet."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.3390\/genes12111810","article-title":"Integrity and stability of PTC bearing CFTR mRNA and relevance to future modulator therapies in cystic fibrosis","volume":"12","author":"Clarke","year":"2021","journal-title":"Genes. (Basel)"},{"key":"B20","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1126\/science.1375392","article-title":"Cystic fibrosis: Molecular biology and therapeutic implications","volume":"256","author":"Collins","year":"1992","journal-title":"Science"},{"key":"B21","doi-asserted-by":"publisher","first-page":"6393","DOI":"10.1038\/s41598-021-85549-z","article-title":"Assisting PNA transport through cystic fibrosis human airway epithelia with biodegradable hybrid lipid-polymer nanoparticles","volume":"11","author":"Comegna","year":"2021","journal-title":"Sci. Rep."},{"key":"B22","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/s42003-020-0909-1","article-title":"The bidirectional relationship between CFTR and lipids","volume":"3","author":"Cottrill","year":"2020","journal-title":"Commun. Biol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.jcf.2021.01.009","article-title":"Targeting G542X CFTR nonsense alleles with ELX-02 restores CFTR function in human-derived intestinal organoids","volume":"20","author":"Crawford","year":"2021","journal-title":"J. Cyst. Fibros."},{"key":"B24","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1089\/nat.2016.0656","article-title":"Molecular mechanisms of antisense oligonucleotides","volume":"27","author":"Crooke","year":"2017","journal-title":"Nucleic Acid. Ther."},{"key":"B25","volume-title":"The hospital for sick children","year":"2022"},{"key":"B26","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1089\/hum.2020.137","article-title":"Treating cystic fibrosis with mRNA and CRISPR","volume":"31","author":"Da Silva Sanchez","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"B27","doi-asserted-by":"publisher","first-page":"15877","DOI":"10.1074\/jbc.M313628200","article-title":"Cardiac expression of the cystic fibrosis transmembrane conductance regulator involves novel exon 1 usage to produce a unique amino-terminal protein","volume":"279","author":"Davies","year":"2004","journal-title":"J. Biol. Chem."},{"key":"B28","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/S2213-2600(16)00023-0","article-title":"Progress in therapies for cystic fibrosis","volume":"4","author":"De Boeck","year":"2016","journal-title":"Lancet Respir. Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.jcf.2021.09.020","article-title":"Functional restoration of CFTR nonsense mutations in intestinal organoids","volume":"21","author":"de Poel","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"B30","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1111\/j.1742-4658.2009.07520.x","article-title":"Alternative splicing: Role of pseudoexons in human disease and potential therapeutic strategies","volume":"277","author":"Dhir","year":"2010","journal-title":"Febs J."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1073\/pnas.0711795105","article-title":"PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model","volume":"105","author":"Du","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B32","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.jcf.2020.02.006","article-title":"Amplifiers co-translationally enhance CFTR biosynthesis via PCBP1-mediated regulation of CFTR mRNA","volume":"19","author":"Dukovski","year":"2020","journal-title":"J. Cyst. Fibros."},{"key":"B33","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.1002\/ppul.24965","article-title":"Emerging technologies for cystic fibrosis transmembrane conductance regulator restoration in all people with CF","volume":"56","author":"Egan","year":"2021","journal-title":"Pediatr. Pulmonol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"102592","DOI":"10.1016\/j.jbc.2022.102592","article-title":"Features and factors that dictate if terminating ribosomes cause or counteract nonsense-mediated mRNA decay","volume":"298","author":"Embree","year":"2022","journal-title":"J. Biol. Chem."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.3390\/cells11121868","article-title":"One size does not fit all: The past, present and future of cystic fibrosis causal therapies","volume":"11","author":"Ensinck","year":"2022","journal-title":"Cells"},{"key":"B36","doi-asserted-by":"publisher","first-page":"112876","DOI":"10.1016\/j.ejmech.2020.112876","article-title":"Treatment of human airway epithelial Calu-3 cells with a peptide-nucleic acid (PNA) targeting the microRNA miR-101-3p is associated with increased expression of the cystic fibrosis Transmembrane Conductance Regulator gene","volume":"209","author":"Fabbri","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"B37","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/978-1-0716-0243-0_12","article-title":"Peptide nucleic acids for MicroRNA targeting","volume":"2105","author":"Gambari","year":"2020","journal-title":"Methods Mol. Biol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1177\/2472555217729790","article-title":"Use of a high-throughput phenotypic screening strategy to identify amplifiers, a novel pharmacological class of small molecules that exhibit functional synergy with potentiators and correctors","volume":"23","author":"Giuliano","year":"2018","journal-title":"SLAS Discov."},{"key":"B39","doi-asserted-by":"publisher","first-page":"6636","DOI":"10.1016\/j.bmcl.2012.08.107","article-title":"Identification of pyrimidine derivatives as hSMG-1 inhibitors","volume":"22","author":"Gopalsamy","year":"2012","journal-title":"Bioorg Med. Chem. Lett."},{"key":"B40","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1128\/MCB.26.6.2237-2246.2006","article-title":"An apparent pseudo-exon acts both as an alternative exon that leads to nonsense-mediated decay and as a zero-length exon","volume":"26","author":"Grellscheid","year":"2006","journal-title":"Mol. Cell. Biol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1086\/381001","article-title":"Variation in a repeat sequence determines whether a common variant of the cystic fibrosis transmembrane conductance regulator gene is pathogenic or benign","volume":"74","author":"Groman","year":"2004","journal-title":"Am. J. Hum. Genet."},{"key":"B42","doi-asserted-by":"publisher","first-page":"102247","DOI":"10.1016\/j.coph.2022.102247","article-title":"CFTR RNA- and DNA-based therapies","volume":"65","author":"Harrison","year":"2022","journal-title":"Curr. Opin. Pharmacol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"3504","DOI":"10.1073\/pnas.0400182101","article-title":"A variable dinucleotide repeat in the CFTR gene contributes to phenotype diversity by forming RNA secondary structures that alter splicing","volume":"101","author":"Hefferon","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B44","doi-asserted-by":"publisher","first-page":"a032656","DOI":"10.1101\/cshperspect.a032656","article-title":"Translation termination and ribosome recycling in eukaryotes","volume":"10","author":"Hellen","year":"2018","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1056\/NEJM199410133311503","article-title":"A novel mutation in the cystic fibrosis gene in patients with pulmonary disease but normal sweat chloride concentrations","volume":"331","author":"Highsmith","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"B46","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/978-1-60327-411-1_2","article-title":"Silent (synonymous) SNPs: Should we care about them?","volume":"578","author":"Hunt","year":"2009","journal-title":"Methods Mol. Biol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"13477","DOI":"10.1074\/jbc.RA118.003192","article-title":"Correcting the F508del-CFTR variant by modulating eukaryotic translation initiation factor 3-mediated translation initiation","volume":"293","author":"Hutt","year":"2018","journal-title":"J. Biol. Chem."},{"key":"B48","volume-title":"KALYDECO [prescribing information]","year":"2020"},{"key":"B49","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/s41586-020-2308-7","article-title":"The mutational constraint spectrum quantified from variation in 141,456 humans","volume":"581","author":"Karczewski","year":"2020","journal-title":"Nature"},{"key":"B50","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1165\/rcmb.2018-0316OC","article-title":"Nonsense-mediated RNA decay pathway inhibition restores expression and function of W1282X CFTR","volume":"61","author":"Keenan","year":"2019","journal-title":"Am. J. Respir. Cell. Mol. Biol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nbt.3784","article-title":"Oligonucleotide therapies for disorders of the nervous system","volume":"35","author":"Khorkova","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"e2114858118","DOI":"10.1073\/pnas.2114858118","article-title":"Exon-skipping antisense oligonucleotides for cystic fibrosis therapy","volume":"119","author":"Kim","year":"2022","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B53","doi-asserted-by":"publisher","first-page":"e2000779","DOI":"10.1371\/journal.pbio.2000779","article-title":"Alteration of protein function by a silent polymorphism linked to tRNA abundance","volume":"15","author":"Kirchner","year":"2017","journal-title":"PLoS Biol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.omtn.2022.04.033","article-title":"Efficient suppression of endogenous CFTR nonsense mutations using anticodon-engineered transfer RNAs","volume":"28","author":"Ko","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"B55","doi-asserted-by":"publisher","first-page":"15912","DOI":"10.1016\/s0021-9258(18)82339-0","article-title":"Characterization of the cystic fibrosis transmembrane conductance regulator promoter region. Chromatin context and tissue-specificity","volume":"268","author":"Koh","year":"1993","journal-title":"J. Biol. Chem."},{"key":"B56","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1126\/science.1138239","article-title":"SNPs, silent but not invisible","volume":"315","author":"KomarGenetics","year":"2007","journal-title":"Science"},{"key":"B57","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.jcf.2019.12.001","article-title":"Functional rescue of c.3846G>A (W1282X) in patient-derived nasal cultures achieved by inhibition of nonsense mediated decay and protein modulators with complementary mechanisms of action","volume":"19","author":"Laselva","year":"2020","journal-title":"J. Cyst. Fibros."},{"key":"B58","doi-asserted-by":"publisher","first-page":"4630","DOI":"10.1096\/fj.13-227330","article-title":"The silent codon change I507-ATC->ATT contributes to the severity of the \u0394F508 CFTR channel dysfunction","volume":"27","author":"Lazrak","year":"2013","journal-title":"Faseb J."},{"key":"B59","doi-asserted-by":"publisher","first-page":"e154571","DOI":"10.1172\/JCI154571","article-title":"Small-molecule eRF3a degraders rescue CFTR nonsense mutations by promoting premature termination codon readthrough","volume":"132","author":"Lee","year":"2022","journal-title":"J. Clin. Invest."},{"key":"B60","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/s41467-019-08329-4","article-title":"Engineered transfer RNAs for suppression of premature termination codons","volume":"10","author":"Lueck","year":"2019","journal-title":"Nat. Commun."},{"key":"B61","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1093\/hmg\/ddu501","article-title":"CFTR mRNA expression is regulated by an upstream open reading frame and RNA secondary structure in its 5' untranslated region","volume":"24","author":"Lukowski","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"B62","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/978-1-0716-0771-8_6","article-title":"Inotersen for the treatment of hereditary transthyretin amyloidosis","volume":"2176","author":"Mahfouz","year":"2020","journal-title":"Methods Mol. Biol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1097\/MCP.0000000000000479","article-title":"Disease-modifying genetic factors in cystic fibrosis","volume":"24","author":"Marson","year":"2018","journal-title":"Curr. Opin. Pulm. Med."},{"key":"B64","doi-asserted-by":"publisher","first-page":"868863","DOI":"10.3389\/fphar.2022.868863","article-title":"Investigating the implications of CFTR exon skipping using a cftr exon 9 deleted mouse model","volume":"13","author":"Martinovich","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"563","DOI":"10.4161\/rna.20231","article-title":"The role of the 3' untranslated region in post-transcriptional regulation of protein expression in mammalian cells","volume":"9","author":"Matoulkova","year":"2012","journal-title":"RNA Biol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/978-1-61779-117-8_16","article-title":"In vitro methods for CFTR biogenesis","volume":"741","author":"Matsumura","year":"2011","journal-title":"Methods Mol. Biol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"a034728","DOI":"10.1101\/cshperspect.a034728","article-title":"What are 3' UTRs doing?","volume":"11","author":"Mayr","year":"2019","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1002\/ppul.25285","article-title":"Cystic fibrosis patients of minority race and ethnicity less likely eligible for CFTR modulators based on CFTR genotype","volume":"56","author":"McGarry","year":"2021","journal-title":"Pediatr. Pulmonol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"6952","DOI":"10.1038\/ncomms7952","article-title":"Nanoparticles that deliver triplex-forming peptide nucleic acid molecules correct F508del CFTR in airway epithelium","volume":"6","author":"McNeer","year":"2015","journal-title":"Nat. Commun."},{"key":"B70","doi-asserted-by":"publisher","first-page":"e26601","DOI":"10.1371\/journal.pone.0026601","article-title":"Synergistic post-transcriptional regulation of the Cystic Fibrosis Transmembrane conductance Regulator (CFTR) by miR-101 and miR-494 specific binding","volume":"6","author":"Megiorni","year":"2011","journal-title":"PLoS One"},{"key":"B71","doi-asserted-by":"publisher","first-page":"7454","DOI":"10.1093\/nar\/gkaa490","article-title":"Antisense oligonucleotide-mediated correction of CFTR splicing improves chloride secretion in cystic fibrosis patient-derived bronchial epithelial cells","volume":"48","author":"Michaels","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"B72","doi-asserted-by":"publisher","first-page":"e2114886119","DOI":"10.1073\/pnas.2114886119","article-title":"Open reading frame correction using splice-switching antisense oligonucleotides for the treatment of cystic fibrosis","volume":"119","author":"Michaels","year":"2022","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B73","doi-asserted-by":"publisher","first-page":"Reviews0004","DOI":"10.1186\/gb-2002-3-3-reviews0004","article-title":"Untranslated regions of mRNAs","volume":"3","author":"Mignone","year":"2002","journal-title":"Genome Biol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.15252\/emmm.201607137","article-title":"Orkambi\u00ae and amplifier co-therapy improves function from a rare CFTR mutation in gene-edited cells and patient tissue","volume":"9","author":"Molinski","year":"2017","journal-title":"EMBO Mol. Med."},{"key":"B75","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1093\/hmg\/ddg079","article-title":"Alternative 5' exons of the CFTR gene show developmental regulation","volume":"12","author":"Mouchel","year":"2003","journal-title":"Hum. Mol. Genet."},{"key":"B76","doi-asserted-by":"publisher","first-page":"e2020599118","DOI":"10.1073\/pnas.2020599118","article-title":"Ataluren and aminoglycosides stimulate read-through of nonsense codons by orthogonal mechanisms","volume":"118","author":"Ng","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B77","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1093\/hmg\/8.13.2339","article-title":"Functional analysis of cis-acting elements regulating the alternative splicing of human CFTR exon 9","volume":"8","author":"Niksic","year":"1999","journal-title":"Hum. Mol. Genet."},{"key":"B78","doi-asserted-by":"publisher","first-page":"7296","DOI":"10.1021\/acs.jmedchem.0c01313","article-title":"Identification of potent, selective, and orally bioavailable small-molecule GSPT1\/2 degraders from a focused library of cereblon modulators","volume":"64","author":"Nishiguchi","year":"2021","journal-title":"J. Med. Chem."},{"key":"B79","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.coph.2017.09.018","article-title":"Transformative therapies for rare CFTR missense alleles","volume":"34","author":"Oliver","year":"2017","journal-title":"Curr. Opin. Pharmacol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"5236","DOI":"10.1172\/JCI124282","article-title":"Slowing ribosome velocity restores folding and function of mutant CFTR","volume":"129","author":"Oliver","year":"2019","journal-title":"J. Clin. Invest."},{"key":"B81","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.coph.2017.09.017","article-title":"The suppression of premature termination codons and the repair of splicing mutations in CFTR","volume":"34","author":"Oren","year":"2017","journal-title":"Curr. Opin. Pharmacol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.jcf.2021.06.003","article-title":"Antisense oligonucleotide-based drug development for Cystic Fibrosis patients carrying the 3849+10 kb C-to-T splicing mutation","volume":"20","author":"Oren","year":"2021","journal-title":"J. Cyst. Fibros."},{"key":"B83","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.jcf.2021.12.012","article-title":"Antisense oligonucleotide splicing modulation as a novel Cystic Fibrosis therapeutic approach for the W1282X nonsense mutation","volume":"21","author":"Oren","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"B84","volume-title":"ORKAMBI [prescribing information]","year":"2019"},{"key":"B85","doi-asserted-by":"publisher","first-page":"21041","DOI":"10.1074\/jbc.M910165199","article-title":"Splicing factors induce cystic fibrosis transmembrane regulator exon 9 skipping through a nonevolutionary conserved intronic element","volume":"275","author":"Pagani","year":"2000","journal-title":"J. Biol. Chem."},{"key":"B86","doi-asserted-by":"publisher","first-page":"9348","DOI":"10.3390\/ijms23169348","article-title":"Combined treatment of bronchial epithelial calu-3 cells with peptide nucleic acids targeting miR-145-5p and miR-101-3p: Synergistic enhancement of the expression of the cystic fibrosis transmembrane conductance regulator (CFTR) gene","volume":"23","author":"Papi","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B87","doi-asserted-by":"publisher","first-page":"e3000396","DOI":"10.1371\/journal.pbio.3000396","article-title":"Inverted translational control of eukaryotic gene expression by ribosome collisions","volume":"17","author":"Park","year":"2019","journal-title":"PLoS Biol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1002\/humu.24306","article-title":"Pseudoexon activation in disease by non-splice site deep intronic sequence variation - wild type pseudoexons constitute high-risk sites in the human genome","volume":"43","author":"Petersen","year":"2022","journal-title":"Hum. Mutat."},{"key":"B89","doi-asserted-by":"publisher","first-page":"eabo0522","DOI":"10.1126\/sciadv.abo0522","article-title":"In vivo correction of cystic fibrosis mediated by PNA nanoparticles","volume":"8","author":"Piotrowski-Daspit","year":"2022","journal-title":"Sci. Adv."},{"key":"B90","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1186\/s12864-019-5864-1","article-title":"Assessing cell-specific effects of genetic variations using tRNA microarrays","volume":"20","author":"Polte","year":"2019","journal-title":"BMC Genomics"},{"key":"B91","doi-asserted-by":"publisher","first-page":"e1641","DOI":"10.1002\/wrna.1641","article-title":"Therapeutic promise of engineered nonsense suppressor tRNAs","volume":"12","author":"Porter","year":"2021","journal-title":"Wiley Interdiscip. Rev. RNA"},{"key":"B92","volume-title":"Yumanity Therapeutics and Proteostasis Therapeutics announce merger agreement [press release]","year":"2020"},{"key":"B93","volume-title":"SpliSense initiates phase 1\/2 study of SPL84, RNA-based therapy, for the treatment of cystic fibrosis [press release]","year":"2022"},{"key":"B94","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1165\/rcmb.2012-0430OC","article-title":"Post-transcriptional regulation of cystic fibrosis transmembrane conductance regulator expression and function by microRNAs","volume":"49","author":"Ramachandran","year":"2013","journal-title":"Am. J. Respir. Cell. Mol. Biol."},{"key":"B95","doi-asserted-by":"publisher","first-page":"e2010612118","DOI":"10.1073\/pnas.2010612118","article-title":"Positive epistasis between disease-causing missense mutations and silent polymorphism with effect on mRNA translation velocity","volume":"118","author":"Rauscher","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B96","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1038\/s41467-022-29935-9","article-title":"CFTR mRNAs with nonsense codons are degraded by the SMG6-mediated endonucleolytic decay pathway","volume":"13","author":"Sanderlin","year":"2022","journal-title":"Nat. Commun."},{"key":"B97","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1016\/j.ymthe.2019.06.016","article-title":"Steric inhibition of 5' UTR regulatory elements results in upregulation of human CFTR","volume":"27","author":"Sasaki","year":"2019","journal-title":"Mol. Ther."},{"key":"B98","doi-asserted-by":"publisher","first-page":"9609","DOI":"10.1158\/0008-5472.CAN-07-2377","article-title":"Silent polymorphisms speak: How they affect pharmacogenomics and the treatment of cancer","volume":"67","author":"Sauna","year":"2007","journal-title":"Cancer Res."},{"key":"B99","doi-asserted-by":"publisher","first-page":"e1007723","DOI":"10.1371\/journal.pgen.1007723","article-title":"Capitalizing on the heterogeneous effects of CFTR nonsense and frameshift variants to inform therapeutic strategy for cystic fibrosis","volume":"14","author":"Sharma","year":"2018","journal-title":"PLoS Genet."},{"key":"B100","doi-asserted-by":"publisher","first-page":"4358","DOI":"10.1038\/s41467-021-24575-x","article-title":"A small molecule that induces translational readthrough of CFTR nonsense mutations by eRF1 depletion","volume":"12","author":"Sharma","year":"2021","journal-title":"Nat. Commun."},{"key":"B101","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/nsmb.2301","article-title":"Translation drives mRNA quality control","volume":"19","author":"Shoemaker","year":"2012","journal-title":"Nat. Struct. Mol. Biol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/wrna.1366","article-title":"Ribosome-based quality control of mRNA and nascent peptides","volume":"8","author":"Simms","year":"2017","journal-title":"Wiley Interdiscip. Rev. RNA"},{"key":"B103","doi-asserted-by":"publisher","first-page":"2633105520973985","DOI":"10.1177\/2633105520973985","article-title":"The first orally deliverable small molecule for the treatment of spinal muscular atrophy","volume":"15","author":"Singh","year":"2020","journal-title":"Neurosci. Insights"},{"key":"B104","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1177\/2472555220962001","article-title":"Identification of compounds that promote readthrough of premature termination codons in the CFTR","volume":"26","author":"Smith","year":"2021","journal-title":"SLAS Discov."},{"key":"B105","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1038\/ng.2745","article-title":"Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene","volume":"45","author":"Sosnay","year":"2013","journal-title":"Nat. Genet."},{"key":"B106","doi-asserted-by":"publisher","first-page":"1015926","DOI":"10.3389\/fphar.2022.1015926","article-title":"Gene therapy for cystic fibrosis: Challenges and prospects","volume":"13","author":"Sui","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B107","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.3390\/molecules25071677","article-title":"A peptide nucleic acid (PNA) masking the miR-145-5p binding site of the 3'UTR of the cystic fibrosis transmembrane conductance regulator (CFTR) mRNA enhances CFTR expression in calu-3 cells","volume":"25","author":"Sultan","year":"2020","journal-title":"Molecules"},{"key":"B108","volume-title":"SYMDEKO [prescribing information]","year":"2020"},{"key":"B109","volume-title":"US CF foundation","year":"2021"},{"key":"B110","volume-title":"TRIKAFTA [prescribing information]","year":"2021"},{"key":"B111","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1007\/s00439-017-1809-4","article-title":"Deep intronic mutations and human disease","volume":"136","author":"Vaz-Drago","year":"2017","journal-title":"Hum. Genet."},{"key":"B112","doi-asserted-by":"publisher","first-page":"e1002462","DOI":"10.1371\/journal.pbio.1002462","article-title":"Ribosomal stalk protein silencing partially corrects the df508-CFTR functional expression defect","volume":"14","author":"Veit","year":"2016","journal-title":"PLoS Biol."},{"key":"B113","doi-asserted-by":"publisher","first-page":"11972","DOI":"10.3390\/ijms222111972","article-title":"Comprehensive analysis of combinatorial pharmacological treatments to correct nonsense mutations in the CFTR gene","volume":"22","author":"Venturini","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B114","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1183\/09031936.00113214","article-title":"Transcription factors and miRNAs that regulate fetal to adult CFTR expression change are new targets for cystic fibrosis","volume":"45","author":"Viart","year":"2015","journal-title":"Eur. Respir. J."},{"key":"B115","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1038\/nature06716","article-title":"Following translation by single ribosomes one codon at a time","volume":"452","author":"Wen","year":"2008","journal-title":"Nature"},{"key":"B116","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.tig.2020.08.010","article-title":"The branched nature of the nonsense-mediated mRNA decay pathway","volume":"37","author":"Yi","year":"2021","journal-title":"Trends Genet."},{"key":"B117","doi-asserted-by":"publisher","first-page":"9140","DOI":"10.1016\/s0021-9258(18)31562-x","article-title":"The cystic fibrosis gene has a \"housekeeping\"-type promoter and is expressed at low levels in cells of epithelial origin","volume":"266","author":"Yoshimura","year":"1991","journal-title":"J. Biol. Chem."},{"key":"B118","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.3390\/molecules22071144","article-title":"Peptide nucleic acids as miRNA target protectors for the treatment of cystic fibrosis","volume":"22","author":"Zarrilli","year":"2017","journal-title":"Molecules"},{"key":"B119","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/0888-7543(91)90503-7","article-title":"Genomic DNA sequence of the cystic fibrosis transmembrane conductance regulator (CFTR) gene","volume":"10","author":"Zielenski","year":"1991","journal-title":"Genomics"}],"container-title":["Frontiers in Genetics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2023.1166529\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T11:42:46Z","timestamp":1682336566000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2023.1166529\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,24]]},"references-count":119,"alternative-id":["10.3389\/fgene.2023.1166529"],"URL":"https:\/\/doi.org\/10.3389\/fgene.2023.1166529","relation":{},"ISSN":["1664-8021"],"issn-type":[{"value":"1664-8021","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,24]]},"article-number":"1166529"}}